Literature DB >> 23825777

The continual search for ideal biomarkers for mesothelioma: the hurdles.

Fraser J Brims1, Y C Gary Lee, Jenette Creaney.   

Abstract

Entities:  

Year:  2013        PMID： 23825777      PMCID： PMC3698297          DOI： 10.3978/j.issn.2072-1439.2013.04.19

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

1.  Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.

Authors:  Kazu Shiomi; Hideaki Miyamoto; Tatsuya Segawa; Yoshiaki Hagiwara; Akinobu Ota; Masahiro Maeda; Kazuhisa Takahashi; Kimihiko Masuda; Yukinori Sakao; Okio Hino
Journal:  Cancer Sci       Date:  2006-06-07       Impact factor: 6.716

2.  Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.

Authors:  Kevin Hollevoet; Kristiaan Nackaerts; Robert Gosselin; Walter De Wever; Lionel Bosquée; Paul De Vuyst; Paul Germonpré; Eliane Kellen; Catherine Legrand; Yoshiro Kishi; Joris R Delanghe; Jan P van Meerbeeck
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

3.  Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model.

Authors:  Y Yamashita; M Yokoyama; E Kobayashi; S Takai; O Hino
Journal:  Biochem Biophys Res Commun       Date:  2000-08-18       Impact factor: 3.575

4.  Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.

Authors:  Harvey I Pass; Dan Lott; Fulvio Lonardo; Michael Harbut; Zhandong Liu; Naimei Tang; Michele Carbone; Craig Webb; Anil Wali
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

5.  Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.

Authors:  Helen E Davies; Ross S Sadler; Silvia Bielsa; Nicholas A Maskell; Najib M Rahman; Robert J O Davies; Berne L Ferry; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2009-03-19       Impact factor: 21.405

6.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

7.  Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.

Authors:  Bogdan D Grigoriu; Bachar Chahine; Anil Vachani; Thomas Gey; Massimo Conti; Daniel H Sterman; Genevieve Marchandise; Henri Porte; Steven M Albelda; Arnaud Scherpereel
Journal:  Am J Respir Crit Care Med       Date:  2009-02-06       Impact factor: 21.405

8.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Molecular cloning and expression of megakaryocyte potentiating factor cDNA.

Authors:  T Kojima; M Oh-eda; K Hattori; Y Taniguchi; M Tamura; N Ochi; N Yamaguchi
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

10.  Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

Authors:  Paul Wheatley-Price; Boming Yang; Demetris Patsios; Devalben Patel; Clement Ma; Wei Xu; Natasha Leighl; Ronald Feld; B C John Cho; Brenda O'Sullivan; Heidi Roberts; Ming Sound Tsao; Martin Tammemagi; Masaki Anraku; Zhuo Chen; Marc de Perrot; Geoffrey Liu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544
View more
  3 in total

1.  Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Authors:  Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan
Journal:  Lung       Date:  2013-10-30       Impact factor: 2.584

2.  Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.

Authors:  Erasmia Rouka; Georgios D Vavougios; Evgeniy I Solenov; Konstantinos I Gourgoulianis; Chrissi Hatzoglou; Sotirios G Zarogiannis
Journal:  Front Physiol       Date:  2017-03-21       Impact factor: 4.566

3.  Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.

Authors:  İsa Döngel; Ali Akbaş; İsmail Benli; Mehmet Bayram
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-06-28       Impact factor: 0.332
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.